Junji Yamanishi

Synergistic functions of phorbol ester and calcium in serotonin release from human platelets

In human platelets, thrombin activates Ca2+-activated, phospholipid-dependent protein kinase (protein kinase C) and mobilizes Ca2+ concomitantly, whereas 12-O-tetradecanoylphorbol-13-acetate (TPA) may be intercalated into membranes and directly activates protein kinase C without mobilization of Ca2+ in sufficient quantities. A series of experiments with TPA and Ca2+-ionophore (A23187) indicates that activation of protein kinase C is a prerequisite requirement for release of serotonin, and that this enzyme activation and Ca2+ mobilization act synergistically to elicit a full cellular response. Both cyclic AMP and cyclic GMP inhibit activation of protein kinase C by prohibiting the signal-dependent breakdown of inositol phospholipid to produce diacyl-glycerol, but none of these cyclic nucleotides prevents the TPA-induced activation of this enzyme.

Effect of cyclic amp on cytoplasmic free calcium in human platelets stimulated by thrombin: Direct measurement with quiǹ2

With the fluorescent Ca2+ indicator quin2, we measured directly cytoplasmic free Ca2+ [( Ca2+]i) in washed human platelets stimulated by thrombin and examined the effect of cyclic AMP on [Ca2+]i levels and 14C-serotonin release. Thrombin (0.2 U/ml) evoked a rise in [Ca2+]i from the basal level of about 100 nM to integral of 3 microM which was fast enough to trigger serotonin release. This rise was inhibited in a dose-dependent manner by preincubation with prostaglandin E1 (PGE1) (0.1-10 microM) or dibutyryl cyclic AMP (0.01 -1 mM). Parallel to this, serotonin release was also inhibited by these drugs. When added to platelets after stimulation by thrombin, PGE1 caused the rapid decrease of elevated [Ca2+]i. These results provide direct evidence that [Ca2+]i levels in platelets are regulated by cyclic AMP.

Inhibitory action of guanosine 3′,5′-monophosphate on thrombin-induced calcium mobilization in human platelets

During thrombin-induced serotonin release from platelets, phosphorylation of myosin light chain was increased. This protein phosphorylation, which is initiated by Ca2+ mobilization, and serotonin release were inhibited progressively by increasing concentrations of sodium nitroprusside, a potent stimulator of platelet guanylate cyclase, or 8-bromo-cyclic GMP. Thrombin-induced increase in cytoplasmic free Ca2+, which was also inhibited by these drugs in a dose-dependent manner. These results provide evidence that an increase in platelet cyclic GMP inhibits thrombin-induced Ca2+ mobilization and prevents platelet activation.

Elevation of cytoplasmic free calcium concentration by stable thromboxane A2 analogue in human platelets

9, 11-Epithio-11, 12-methano-thromboxane A2 (STA2), a stable analogue of thromboxane A2, caused a rapid rise in cytoplasmic free Ca2+ concentration ([Ca2+]i) in human platelets as measured with the fluorescent Ca2+ indicator quin2. Concomitantly, this compound induced phosphorylation of myosin light chain which is catalyzed by Ca2+, calmodulin-dependent protein kinase. These reactions were fast enough to trigger serotonin release. 13-Azaprostanoic acid, a receptor level antagonist of thromboxane A2 inhibited STA2-induced elevation of [Ca2+]i, phosphorylation of myosin light chain and serotonin release. These results provide evidence that STA2 interacts with a thromboxane A2 receptor which leads to elevation of [Ca2+]i.

A Circulating Na+-K+ATPase Inhibitor, Erythrocyte Sodium Transport and Hypertension in Patients with Chronic Renal Failure

The level of circulating Na+-K+ATPase inhibitor (% inhibition), erythrocyte ouabain-sensitive 22Na+ efflux rate constant (Kos) and erythrocyte sodium content (RBC Na) were measured in 11 undialysed patients with chronic renal failure, 16 patients on chronic hemodialysis and 16 age-matched normotensive healthy controls. In uremics, % inhibition was significantly higher than that in the controls (p less than 0.001). There were significant correlations between % inhibition and both mean blood pressure (r = 0.74, p less than 0.001) and Kos (r = -0.47, p less than 0.005) for all the groups combined. Hypertensive uremics showed significantly higher % inhibition, lower Kos and higher RBC Na compared with normotensive ones. These data suggest that the elevated level of circulating Na+-K+ ATPase inhibitor may, at least in part, account for the pathogenesis of hypertension in patients with chronic renal failure.

Protein phosphorylation and diglyceride production during serotonin release induced by epinephrine plus ADP in human platelets

Epinephrine (1 microM) plus ADP (5 microM) induced serotonin release from human platelets although neither epinephrine nor ADP alone brought about such a release. During this release reaction, the phosphorylation of 40K-dalton protein was induced to an extent similar to that induced by 0.5 unit/ml thrombin. The amount of diglyceride (DG) produced by epinephrine plus ADP, however, was much smaller than that produced by thrombin. The reaction velocities of these reactions induced by epinephrine plus ADP were slower than those induced by thrombin. Epinephrine or ADP alone hardly produced any DG and induced 40K-dalton protein phosphorylation only slightly. Indomethacin (1 microgram/ml), a cyclooxygenase inhibitor, remarkably inhibited epinephrine plus ADP induced serotonin release, 40K-dalton protein phosphorylation and DG production although this agent had little effect on the same reactions induced by thrombin. These results suggest that prostaglandin endoperoxides or thromboxane A2 may be involved in serotonin release, 40K-dalton protein phosphorylation and DG production induced by epinephrine plus ADP.

Calcium Supplementation in Salt-Dependent Hypertension

To clarify the mechanism of the antihypertensive effect of oral Ca loading, we studied the effect of Ca supplementation on salt-induced blood pressure elevations in patients with essential hypertension and DOCA-salt hypertensive rats. When the diet was changed from low to high salt (300 mEq/day), the percent increase in mean blood pressure was smaller (p less than 0.01) in the Ca-supplemented (2,160 mg/day) patients than in the Ca-restricted (250 mg/day) ones. Oral Ca loading resulted in a smaller weight gain, a greater urinary sodium excretion, and an increase in red cell Mg. In the experimental study, high Ca (4% CaCl2) intake attenuated the blood pressure elevation in DOCA-salt-treated rats, accompanied with an increase in urinary sodium excretion, with the resultant attenuation in intra- and extracellular sodium retention. The decrease in catecholamine contents of hearts was improved, and a higher survival rate was observed in Ca-supplemented DOCA-salt rats. The results suggest that Ca supplementation may prevent a rise in BP in salt-dependent hypertension by inducing natriuresis with the resultant attenuation in sodium retention. The altered intracellular Mg level in hypertensive patients and the normalization of enhanced sympathetic nervous activity in DOCA-salt rats may, in part, be involved in its mechanism.